Back to Search Start Over

Case Report: Ziprasidone induced neuroleptic malignant syndrome.

Authors :
Sedhai YR
Atreya A
Phuyal P
Basnyat S
Pokhrel S
Source :
F1000Research [F1000Res] 2021 Feb 17; Vol. 10, pp. 124. Date of Electronic Publication: 2021 Feb 17 (Print Publication: 2021).
Publication Year :
2021

Abstract

Neuroleptic malignant syndrome (NMS) is a well-recognized neurologic emergency. It presents with classic features including hyperthermia, autonomic instability, muscle hypertonia, and mental status changes. The syndrome is potentially fatal and is associated with significant morbidity due to complications such as rhabdomyolysis, acute kidney injury, and ventricular arrhythmias due to the trans-cellular electrolyte shift. NMS is conventionally associated with the first-generation antipsychotic agents, however, has been described with the use of atypical and novel antipsychotics including Ziprasidone. A case of NMS with Ziprasidone use at the therapeutic dose is reported here.<br />Competing Interests: No competing interests were disclosed.<br /> (Copyright: © 2021 Sedhai YR et al.)

Details

Language :
English
ISSN :
2046-1402
Volume :
10
Database :
MEDLINE
Journal :
F1000Research
Publication Type :
Academic Journal
Accession number :
33763203
Full Text :
https://doi.org/10.12688/f1000research.51094.1